Source comparison
Introduction: Central vs Peripheral Mechanisms in Erectile Biology
Erectile dysfunction (ED) affects an estimated 40% of men over 40, with prevalence increasing substantially with age. The dominant pharmacological approach — phosphodiesterase type 5 (PDE5) inhibitors (sildenafil, tadalafil, vardenafil) — works through a perip
This comparison does not assign a generated winner or score.
- Erectile dysfunction (ED) affects an estimated 40% of men over 40, with prevalence increasing substantially with age. The dominant pharmacological approach — phosphodiesterase type 5 (PDE5) inhibitors (sildenafil, tadalafil, vardenafil) — works through a peripheral vascular mechanism: preventing cGMP degradation in penile smooth muscle, thereby prolonging NO-mediated vasodilation and facilitating erection. While PDE5 inhibitors are effective for many patients, they require sexual stimulation to be effective, do not address absent or reduced sexual desire (libido), and are ineffective or contraindicated in a substantial proportion of patients.
- PT-141 (bremelanotide) operates through an entirely different and centrally-mediated mechanism — activation of melanocortin receptors in the hypothalamus and related CNS structures that govern sexual motivation and arousal. This central mechanism produces pro-erectile and pro-desire effects that are complementary to PDE5 inhibitor biology, addressing components of sexual dysfunction that peripheral vascular agents cannot.